PURPOSE: To assess treatment outcome after definitive radiotherapy for @entity5 retrospective analysis of the clinical data was performed. METHODS AND MATERIALS: We enrolled 265 @entity1 with @entity5 who were treated with combined external beam radiotherapy [mean +/- standard deviation (SD), 50.3 +/- 1.8 Gy; range 40-70) and intracavitary brachytherapy (ICBT) (mean +/- SD, 19.8 +/- 2.4 Gy; range 10-32) using a high-dose-rate 60Co source. We retrospectively analyzed, as measures of the therapeutic outcome, the @entity1168 ( @entity1168 ), @entity4557 ( @entity4557 ), @entity1168 ( @entity1168 ), @entity3 ( @entity3 ), and late complication. RESULTS: The 5-year @entity1168 , @entity4557 , and @entity1168 rates (n = 265) were 50.7%, 57.1%, and 71.2%, respectively. Univariate analysis revealed a significant favorable effect on the @entity1168 rate for complete response (CR) (p = 0.024), maximum @entity5 diameter < 6 cm (SML) (p = 0.0009), Karnofsky performance score > or =70 (p = 0.046), age <75 years (p = 0.0043), hemoglobin (Hb) concentration of > or =9 g/dl (p = 0.0005), and histopathological diagnosis of @entity957 ( @entity957 ) (p = 0.0089). In the multivariate analysis, Hb, @entity957 , SML, and CR remained significant prognostic factors. In both univariate and multivariate analysis, SML, Hb, age, and @entity957 showed significant effects on the @entity4557 rate. Age > or =60 years (p = 0.017), Hb > or =9 g/dl (p = 0.0039), and SML (p = 0.0046) were significant favorable prognostic factors for the @entity1168 rate identified by univariate analysis. In addition, advanced age, SML, and @entity957 showed significant beneficial effects on the @entity1168 rate in the multivariate analysis. @entity3 developed in 21.1% of @entity1 , and the groups with Hb < 9 g/dl (p < 0.005), Karnofsky performance score of <70 (p < 0.001), and dose at point A in the ICBT < 16 Gy (p < 0.005) developed a significantly greater incidence of @entity3 than did the groups without. The 5-year incidence was 2.6% for major @entity1494 and 8.3% for major @entity532 . The radiation dose in the subgroup with @entity532 was significantly greater than that in the subgroup without complications. CONCLUSION: In @entity1 with @entity5 , @entity5 size, concentration of Hb, and histopathological diagnosis are strong prognostic factors for the therapeutic outcome. The ICBT dose in our study was small compared to the reported data, but the outcome was quite comparable. Thus, the dose we used might be the minimum required. However, locoregional control still remains an important problem. It is necessary to attain the optimal dose distribution in both the target volume and in critical organs. In high-risk @entity1 , combined use of chemotherapy is crucial to improve the response to radiation.

Definitive radiotherapy combined with high-dose-rate brachytherapy for @entity5 of the uterine cervix: retrospective analysis of prognostic factors concerning XXXX characteristics and treatment parameters.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival rate'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder complication'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Stage III cervical carcinoma', 'tumor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'SCC'] @entity532 :: ('MESH:D003925', 'Disease') :: ['rectal complication'] @entity3 :: ('MESH:D009362', 'Disease') :: ['DM', 'distant metastasis'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['LREF', 'OAS', 'locoregional event-free rate', 'overall survival rate']
@entity1 :: (9606,Species) :: ['patient']
